ALAnastasia A. Lovenger

Anastasia A. Lovenger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anastasia A. Lovenger has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    New undifferentiated pleomorphic sarcoma cell line UPS134 for in vitro and in vivo studies

    by Polina A. Shtompel, Sofya A. Khazanova, Ekaterina S. Trapeznikova, Victoria Yu. Zinovieva, Anastasia A. Lovenger, Anastasia A. Tararykova, Beniamin Yu. Bokhyan, Natalia V. Khromova, Pavel B. Kopnin, Timur I. Fetisov, et al.

    Background. Due to the limited number of cell lines, as well as the high heterogeneity of undifferentiated pleomorphic sarcomas (UPS), the creation of new stable cell lines is relevant. Aim. Obtaining a stable cell line from a sample of UPS obtained during surgery to model carcinogenesis processes in vitro and in vivo. Materials and methods. Cells were isolated from a tumor sample from a patient diagnosed with UPS. After passage 40 and stable growth, the proliferation rate, cell morphology, and growth ability in 3D culture conditions were assessed. To assess tumorigenicity, the cell suspension was injected into BALB / c nu / nu athymic mice. On the 15th day of the experiment, the tumor was removed, its volume was measured, and it was examined histologically. Using short tandem repeat (STR) analysis, the cells of the resulting line were examined for the presence of human cell markers and their uniqueness. The chemosensitivity of the cells was assessed using the resazurin test. Results. Stable growth and formation of spheroids under 3D culturing conditions were demonstrated for the cell culture. All mice inoculated with the UPS134 cell suspension showed tumor growth, and by day 14 of the experiment its average size was 28,7 mm3. Histologically, the tumor is similar in morphology to UPS, except for a smaller amount of myxoid and less polymorphism. The cells of the obtained line were shown to contain all analyzed genetic markers of human cells, and also that the STR data of the obtained line did not coincide with the STR of other lines. For doxorubicin, gemcitabine and docetaxel, IC50 (inhibitory concentration) were determined to be 15, 6.5 and 10 % of the plasma peak concentration, respectively. Conclusions. We obtained a new cell line UPS134, which can be further used to study the pathogenesis of UPS, as well as in preclinical studies of new antitumor agents in vitro and in vivo.

  • Open Access

    Aggressive Dermatofibroma with Metastatic Lesions of the Lymph Nodes, Lungs, and Bones. Description of the Clinical Case. Literature Review

    by Ольга Михайловна Романцова, Екатерина Евгеньевна Зеленова, Хаяле Асиф Кызы Алескерова, Анастасия Алексеевна Ловенгер, Денис Борисович Хестанов, Елена Вячеславовна Шарапова, Татьяна Сергеевна Белышева, Елена Владимировна Михайлова, Светлана Рафаэлевна Варфоломеева

    Дерматофиброма (доброкачественная фиброзная гистиоцитома) относится к доброкачественным новообразованиям кожи, характеризующимся медленным ростом и способностью к метастазированию. Патогенез этой неоплазии неизвестен, но ряд авторов описывают связь с гистогенетическими прекапиллярными изменениями. Зачастую опухоль характеризуется доброкачественным поведением, хотя для нее типично частое рецидивирование, даже при радикальном хирургическом лечении. Случаи метастазирования этих опухолей впервые описаны в 1979 г. Ф. Энцингером в журнале «Cancer». С тех пор в мире зарегистрировано 10 случаев с похожим агрессивным течением у детей. Ввиду редкости патологии стандарты лечения отсутствуют, а прогноз является неопределенным. Нами представлен клинический случай метастазирующей дерматофибромы у девочки 13 лет с крайне агрессивным течением. При первичной диагностике выявлен узел в области бедра с деструкцией прилежащих костных структур, прорастанием в регионарные лимфатические узлы и наличием мультифокального метастатического поражения легких.

  • Open Access

    Distal resection margin in colorectal surgery in vivo and after formalin fixation

    by A. S. Gorbunova, A. A. Aniskin, D. V. Kuzmichev, Z. Z. Mamedli, A. V. Polynovsky, A. A. Lovenger, F. M. Abdul

    Introduction. Historically, the standard for distal margin in rectal cancer surgery has been the 5 cm «rule». Currently, there is a trend to reduction the distal surgical margin. However, intraoperative specimen measurements and histological examination data differ. The phenomenon of surgical shrinkage plays a significant role, especially in determining the distal resection margin, as intraoperative data may not coincide with measurement after fixation of the specimen. Possible differences may lead to doubts about the oncological adequacy of the performed resection boundaries.Aim. To examine the shrinkage effect of distal resection margin in colorectal cancer after organ formalin fixation.Materials and methods. The prospective analysis included data of 20 patients with histologically confirmed rectal cancer and sigmoid cancer (adenocarcinoma G1–3) for whom surgical treatment is recommended. The distance between the lower edge of tumor to the distal resection margin was measured after resection (in vivo) and after 5–12 minutes after the last measurement. Then the determination of this distance was made after formalin fixation (in vitro).Results. The analysis revealed that the average shrinkage of the distal resection margin from in vivo to ex vivo was 30.5 mm (25,5 %) (p = 0.0001). The average shrinkage between in vivo and in vitro bowel samples was 51.0 mm.Conclusions. Measurement of the distal resection margin under different conditions influences the estimation of the oncological clearence in interpreting the results of pathological report and determining the results of treatment.


  • Open Access

    Changes in the expression of genes that regulate apoptosis as a factor in the development of chemoresistance in soft tissue sarcoma

    by T. I. Fetisov, S. A. Khazanova, P. A. Shtompel, E. S. Trapeznikova, A. A. Tararykova, V. Yu. Zinovyeva, V. I. Marshall, A. A. Lowenger, I. S. Kupaeva, D. V. Rogozhin, et al.

    Introduction. The active use of highly toxic chemotherapy in the treatment of soft tissue sarcomas determines the need to search for criteria and markers of chemoresistance of patients to the therapy.Aim. To study the connection between tumor cell resistance to chemotherapy and expression levels of apoptosis-regulating proteins (PUMA, PMAIP-1, PIDD-1, AIFM-2, Bax, GADD45a) in primary cultures of soft tissue sarcomas.Materials and methods. Primary cultures of soft tissue sarcomas were obtained using enzymatic digestion, cell death was evaluated using resazurine assay. Gene expression was measured using real-time polymerase chain reaction, protein levels using immunoblotting assay.Results. 73 primary cultures of soft tissue sarcomas were obtained, for which chemosensitivity to doxorubicin, ifosfamide, docetaxel, gemcitabine, pazopanib and their combinations was determined using a resazurin cytotoxicity test. Associations of AIFM-2 gene expression with resistance to pazopanib, doxorubicin and its combination with ifosfamide were found in liposarcoma, synovial and undifferentiated pleomorphic sarcomas. In addition, associations between the expression of the Bax, PUMA, PMAIP-1, GADD45a and PIDD-1 genes and resistance to the studied drugs in various nosological subgroups of sarcomas were identified. When studying the amount of protein, it was revealed that undifferentiated pleomorphic and synovial sarcomas with a low content of GADD45a are more resistant to the studied drugs. Liposarcomas with high Bax expression are more resistant to docetaxel and gemcitabine, while synovial sarcomas with high Bax expression are more sensitive to doxorubicin and ifosfamide.Conclusion. The data obtained indicate a relationship between the activity of the studied genes-regulators of apoptosis and resistance to drugs used in the treatment of soft tissue sarcomas.